NEW YORK, August 8, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Today, Investors' Reports announced new research reports
highlighting Zoetis Inc. (NYSE: ZTS), GlaxoSmithKline plc (ADR)
(NYSE: GSK), Actavis Inc. (NYSE: ACT), Kindred Healthcare, Inc.
(NYSE: KND), and TESARO Inc. (NASDAQ: TSRO). Today's readers may
access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.
Zoetis Inc. Research Report
On August 4, 2013, Zoetis Inc.
(Zoetis) announced that its joint venture in China has received an approval by the Ministry
of Agriculture of the People's Republic
of China for Rui Lan An, a
specialized vaccine that helps control the highly pathogenic
porcine reproductive and respiratory syndrome (HP PRRS). The
Company informed that Rui Lan An,
which is the first vaccine from the joint venture that was entered
in order to develop and manufacture animal vaccines designed to
meet the needs of China's
livestock producers, will be launched later in August 2013. Stefan
Weiskopf, Executive Vice President and President, Asia
Pacific Region at Zoetis, said, "Rui Lan
An exemplifies the commitment of our joint venture to
develop and manufacture quality vaccines well matched to the local
health challenges facing China's
pork industry." The Full Research Report on Zoetis Inc. - including
full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-05/ZTS]
--
GlaxoSmithKline plc (ADR) Research
Report
On August 2, 2013, GlaxoSmithKline
plc (GSK) announced that the U.S. Prescription Drug User Fee Act
(PDUFA) goal date for albiglutide, an investigational
once-weekly treatment for adult patients with type 2 diabetes, was
extended by three months to April 15,
2014 to provide ample time for a full review of information
submitted by GSK in response to the Food and Drug Administration
(FDA)'s requests. GSK stated that it has submitted a Biologics
License Application to the US FDA for albiglutide on
January 14, 2013, followed by the
submission of a Marketing Authorization Application (MAA) to the
European Medicines Agency on March 7,
2013. The Company also informed that the EMA filing is
progressing according to schedule. The Full Research Report on
GlaxoSmithKline plc (ADR) - including full detailed breakdown,
analyst ratings and price targets - is available to download free
of charge at:
[http://www.investorsreports.com/report/2013-08-05/GSK]
--
Actavis Inc. Research Report
On August 2, 2013, Actavis, Inc.
(Actavis) announced that Actavis Limited, Bank of America N.A. (as
Administrative Agent) and a syndicate of banks participating as
lenders have entered into a new senior unsecured term loan credit
and guaranty agreement, under which the lenders to the agreement
will provide loans to certain entities of Warner Chilcott plc (Warner Chilcott) in an aggregate amount not
exceeding $2 billion and comprising
of a $1 billion three-year Tranche
and a $1 billion five-year Tranche.
Actavis said that the proceeds from borrowings will be used to
finance the repayment of existing credit facilities of the WC
Borrowers and pay transaction fees and expenses. In addition,
Actavis stated that the Company, Bank of America, N.A., and a
syndicate of banks participating as lenders have agreed to amend
and restate Actavis' existing $750
million senior unsecured revolving credit loan facility
dated as of September 16, 2011, and
also to amend and restate Actavis' existing $1.8 billion senior unsecured term loan credit
facility dated June 22, 2012.The Full
Research Report on Actavis Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-08-05/ACT]
--
Kindred Healthcare, Inc. Research
Report
On August 5, 2013, Kindred
Healthcare Inc. (Kindred Healthcare) reported its Q2 2013 financial
results. The Company reported a decline in revenues of 1% YoY to
$1.4 billion. Net income was
$1.7 million or $0.03 per diluted share, compared to net income
of $15.5 million or $0.29 per diluted share in Q2 2012. Commenting on
the results, Paul J. Diaz, Kindred
Healthcare CEO said, "Despite significant reimbursement pressures
brought on by federal sequestration cuts of 2% beginning
April 1, Kindred reported solid
second quarter core results." He added, "In addition, we are
continuing to see the benefits of the Ventas nursing center
transition to our continuing operations. The disposition of these
54 nursing centers lifted our earnings from continuing operations
by $0.11 per diluted share in the
first half of 2013." The Full Research Report on Kindred
Healthcare, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge
at: [http://www.investorsreports.com/report/2013-08-05/KND]
--
TESARO Inc. Research Report
On July 25, 2013, TESARO Inc.
(TESARO) reported its Q2 2013 financial results. Research and
development expenses increased 57.6% YoY to $18.2 million. Net loss was $21.6 million or $0.67 per diluted share in Q2 2013, compared to
net loss of $20.2 million or
$21.31 per diluted share in Q2 2012.
Commenting on the quarter's performance, Lonnie Moulder, CEO of TESARO, said, "TESARO is
well positioned to meet several significant milestones in the
second half of this year. We plan to report top-line results from
the rolapitant pivotal program by year end, and we remain on track
to begin enrollment in a Phase 3 study of niraparib in patients
with BRCA-positive breast cancer. In addition, we look forward to
continued enrollment in our Phase 3 trial of niraparib for ovarian
cancer and to the first presentation of TSR-011 clinical data in
September." The Full Research Report on TESARO Inc. - including
full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-06/TSRO]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by a CFA. However, we are only
human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us
at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Equity News Network. An outsourced research services provider has,
through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according
to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as
to the accuracy or completeness or fitness for a purpose
(investment or otherwise), of the information provided in this
document. This information is not to be construed as personal
financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold
any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may
be occasioned at the time of printing of this document or any
error, mistake or shortcoming. No liability is accepted by Equity
News Network whatsoever for any direct, indirect or consequential
loss arising from the use of this document. Equity News Network
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Equity News Network
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
InvestorsReports.com
SOURCE Investors' Reports